Evelo Biosciences to Report First Quarter 2020 Financial Results on Monday, May 11, 2020
Rhea-AI Summary
Evelo Biosciences (Nasdaq: EVLO) plans to host a conference call and live webcast on May 11, 2020, at 8:30 a.m. ET to report its Q1 2020 financial results and discuss business highlights. The call can be accessed via phone or through a webcast on Evelo's website. Evelo specializes in developing oral biologics that target the small intestinal axis (SINTAX), with a focus on chronic diseases and cancer. The company has four product candidates aimed at treating inflammatory diseases and cancer.
Positive
- None.
Negative
- None.
News Market Reaction – EVLO
In the trading session that priced this news, EVLO declined 8.97%, reflecting a notable negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., May 04, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Monday, May 11, 2020 to report its first quarter 2020 financial results and discuss business highlights.
To access the live conference call, please dial 866-795-3242 (domestic) or 409-937-8909 (international) and refer to conference ID 2186056. A live webcast of the event will also be available under “News and Events” in the Investors section of Evelo's website at http://ir.evelobio.com. The archived webcast will be available on Evelo's website approximately two hours after the completion of the event and will be available for 30 days following the call.
About Evelo Biosciences
Evelo Biosciences is a clinical stage biotechnology company developing oral biologics that act on SINTAX™, the small intestinal axis with systemic therapeutic effects. SINTAX plays a central role in governing the immune, metabolic and neurological systems. The company’s first product candidates are monoclonal microbials, single strains of microbes selected for defined pharmacological properties. Evelo’s therapies have the potential to be effective, safe and affordable medicines to improve the lives of people with chronic diseases and cancer.
Evelo currently has four product candidates: EDP1815, EDP1867, and EDP2939 for the treatment of inflammatory diseases, and EDP1503 for the treatment of cancer. Evelo is also advancing additional oral biologics through preclinical development in other disease areas.
For more information, please visit www.evelobio.com and engage with Evelo on LinkedIn.
Contact
Evelo Biosciences
Jessica Cotrone, 978-760-5622
jcotrone@evelobio.com